ISLB 2021 Annual Meeting
October 22nd 2021 - Virtual Congress


Who should attend?

  • Translational/clinical researchers

  • Physicians 

  • Pathologists, Molecular Pathologists and Molecular Biologists

  • Oncologists 

  • Clinical trainees, PhD and other students

  • Industry and Molecular diagnostics sector

  • Patients associations and advocacy

All lectures will be available to watch on demand from: October 22nd 2021, at 8:00 AM CET TIME
Untitled design (9).png
Dr Charles Swanton 10:00 am CEST
live-icon-png-94785-free-icons-library-live-icon-png-600_600_edited (1).png
The Francis Crick Institute - Cancer Research UK - University College London Cancer Institute, UK
Tumor evolution through Liquid Biopsy
Ponentes Perú 2021 (49) (1).png
Dr Catherine Alix-Panabieres 10:00 am CEST
live-icon-png-94785-free-icons-library-live-icon-png-600_600_edited (1).png
The Laboratory 'Cellules Circulantes Rares Humaines ' (LCCRH) University Medical Center of Montpellier in France (University of Montpellier - UM), France
Role of Circulating Tumor Cells in Metastatic Cascade
live-icon-png-94785-free-icons-library-live-icon-png-600_600_edited (1).png
TRACK 1     Basic and Discovery Research of Liquid Biopsy
Untitled design (51).png
Dr Juan Manuel Falcón
Ikerbasque Research Professor at CIC bioGUNE, Derio, Bizkaia, Spain
Use of metabolomics to understand treatment resistance
Untitled design (38).png
Dr Sabine Kasimir-Bauer
Associate Professor, University of Duisburg Essen, Germany
Phenotypic and functional analyses of CTC : Sab
Dr Nicola Aceto
Swiss Federal Institute of Technology (ETH) Zurich, Switzerland
Biology and vulnerabilities of CTC clusters
Untitled design - 2021-10-13T202811.484.png
Dr Qiang Zang

Robert H Lurie Comprehensive Cancer Center, Northwestern University,

Chicago, Illinois, USA

Culture of Circulating Tumor Cells reality and xenograft
Untitled design (53).png
Dr Héctor Peinado
Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Metastatic niche and Extracellular Vesicles
Untitled design (71).png
Dr Kenneth O'Byrne
Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia
Novel diagnostic exosomal protein and genomic biomarkers in cancer
live-icon-png-94785-free-icons-library-live-icon-png-600_600_edited (1).png
image Stephanie (200x200px)_edited.png
Stephanie Jordaens PhD
Biomedical Scientist, NOVOSANIS, Belgium
Urine as the golden sample for cancer biomarker detection
TRACK 2     Translational Research in Liquid Biopsy
Controversy session: Copy Number Variation evaluation in Liquid Biopsy
Untitled design (18).png
CONS ► Dr Lynette M. Sholl
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
Untitled design (19).png
PROS ► Dr Philip Mack
University of California Davis Comprehensive Cancer Center, Sacramento, CA - Mount Sinai Tisch Cancer Institute, New York, NY, USA
Untitled design (54).png
Dr Miguel Angel Molina-Vila
Pangaea Oncology, Quirón Dexeus University Hospital, Barcelona, Spain
RNA analysis liquid biopsies of cancer patients: from fusion detection to gene signatures
rolfo 2.jpg
Dr Christian Rolfo
Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai, New York, NY, USA
ISLB President - Congress welcome and introduction
Untitled design (21).png
Dr Federica Di Nicolantonio
Laboratory Molecular Oncology at the Candiolo Cancer Institute IRCCS - Candiolo (Torino), Italy
Molecular mechanisms of cell free DNA release by colorectal cancer
Untitled design (22).png
Dr Umberto Malapelle
Department of Public Health, University of Naples Federico II, Naples, Italy
Molecular mechanisms of cell free DNA release in solid tumors
live-icon-png-94785-free-icons-library-live-icon-png-600_600_edited (1).png
TRACK 3     Current clinical application of Liquid Biopsy
Untitled design (13).png
Dr Natasha Leighl
Medical Oncology, Princess Margaret, Toronto, ON, Canada
How to balance Next Generation Tumor Tissue testing versus Liquid Biopsy algorithms in the clinic
Untitled design (15).png
Dr Charu Aggarwal
Dept of Medicine, Division of Hem/Onc, University of Pennsylvania, PA, USA
Identifying mechanisms of Acquired Resistance in Oncogene-driven Cancers
Untitled design (16).png
Dr Maria E. Arcila
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Liquid Biopsy: Institutional testing platforms versus Central Laboratory
Untitled design (14).png
Dr Sarah-Jane Dawson
University of Melbourne, Australia
Liquid biopsy for targeting treatment resistance in Breast Cancer: A moving target
Untitled design (17).png
Dr Heinz Josef Lenz
University of South California USC, USA
Molecular Landscape in Colorectal Cancer: Opportunities for Liquid Biopsy
Untitled design (25).png
Dr Chiara Cremolini
University of Pisa, Azienda Ospedaliero-Universitaria Pisana, at the Tuscan Tumor Institute in Pisa, Toscana, Italy
ctDNA for treatment selection and treatment resistance in colon cancer
Untitled design (26).png
Dr Sergio Marchini
IRCCS, Humanitas Research Hospital, Milan, Italy
Clinical application of liquid biopsies to detect somatic BRCA1/2mutation in ovarian cancer
Dr Johann De Bono.jpg
Dr Johann De Bono
The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK
Clinical Utility of Liquid Biopsy in Advanced Prostate Cancer
Untitled design (27).png
Dr David Gandara
Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California, USA
Liquid Biopsy in the clinical management of NSCLC patients
TRACK 4     Expanding clinical application of Liquid Biopsy
Untitled design (31).png
Dr Lillian Siu
Princess Margaret, Ontario, Canada
Circulating Biomarkers for Immunotherapy: How to integrate in clinical trials
Untitled design (32).png
Dr Pier Vitale Nuzzo
Dana Farber Cancer Institute, Boston, MA, USA
Epigenetic and Liquid Biopsy
Untitled design (33).png
Dr Alberto Bardelli
Candiolo Cancer Institute IRCCS - Candiolo (Torino), Italy
Liquid biopsy driven, interventional clinical trials in CRC
Dr Toni Choueiri.jpg
Dr Toni Choueiri
Dana Farber Cancer Institute, Boston, MA, USA
Integrating ctDNA and tissue genomic profiling in renal cancer
Untitled design (30).png
Dr Eloísa Jantus Lewintre
Universitat Politècnica de València, Spain
Characterization of circulating TCR repertoire.
Role as biomarker for immunotherapy in NSCLC
Untitled design (35).png
Dr Luis Raez
Memorial Healthcare System, Pembroke Pines, USA
Monitoring Clinical Outcomes with Liquid biopsies (cfDNA and cfRNA) 
Untitled design (36).png
Dr Nicole Kruderer
Advanced Cancer Research Group, Kirkland, Washington

Comparative effectiveness of ctDNA in Breast Cancer 

live-icon-png-94785-free-icons-library-live-icon-png-600_600_edited (1).png
Dr Leomar Y Ballester
University of Texas Health Science at Houston, USA
Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid of Cancer Patients
TRACK 5     Future of Liquid Biopsy
Untitled design (39).png
Dr Andrés Cardona

Research director en "Luis Carlos Sarmiento Angulo" Cancer Treatment and Research Center (CTIC), Colombia

Pan-methylation analysis in liquid biopsy: a novel perspective
Untitled design (40).png
Dr Max Diehn
Stanford University, Stanford, CA, USA
Lung Cancer Screening
Untitled design (41).png
Dr Wishart David
University of Alberta, Edmonton, Alberta, Canada
Liquid Biopsy in Cancer Screening: The Contribution of Metabolomics
Untitled design (42).png
Dr Aadel Chaudhuri
Washington University School of Medicine, St. Louis, USA
The evolving role of MRD in Solid Tumors
Untitled design (24).png
Dr Maria Jose Serrano
Centro Pfizer – Universidad de Granada – Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Spain
Cancer interception beyond ctDNA
Untitled design (43).png
Dr Chris Abbosh
The Francis Crick Institute - Cancer Research UK - University College London Cancer Institute, UK
ctDNA Biomarker of Relapse After Resection in Early NSCLC
live-icon-png-94785-free-icons-library-live-icon-png-600_600_edited (1).png
David Spetzler, MS, PhD, MBA
Caris Life Sciences - President and Chief Scientific Officer, AZ, USA
Transforming Liquid Biopsy: Advancing Clinical Utility for Physicians and Patients
TRACK 6     Liquid Biopsy Clinical Application Challenges and Opportunities Worldwide
Untitled design (44).png
Dr Amy Moore
VP, Global Engagement and Patients Partnership LUNGevity, USA
Role of the advocacy in Liquid Biopsy
Untitled design (45).png
RN, ONC, Allison Gittens
Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA
Molecular Nursing:  a new approach for testing increasing and Liquid Biopsy awareness
Untitled design (46).png
Dr Valeria Denninghoff
University of Buenos Aires (UBA) - National Council for Scientific and Technical Research (CONICET), Argentina
Clinical Application in Latin America: Why so complicated?
Untitled design (47).png
Dr Ullas Batra
Rajiv Gandhi Cancer Institute, Delhi, India
Clinical Application in India: It’s Universal Use a reality or a mirage?
Untitled design (48).png
Dr Ola Khorshid
National Cancer Institute, Cairo, Egypt
Clinical Application in MENA (Middle East and North Africa) Region: Different realities
Untitled design (49).png
Dr Cardinale Smith
Center for Thoracic Oncology, Tisch Cancer Institute, Icahn school of Medicine at Mount Sinai, New York, NY, USA
Disparities in Molecular Testing
Untitled design (50).png
Dana Connors
ILSA, Foundation for the National Institutes of Health, USA
ILSA community: a partnership for standardization of Liquid Biopsy
FDA Initiatives for Liquid Biopsy application and standardization
live-icon-png-94785-free-icons-library-live-icon-png-600_600_edited (1).png
Untitled design - 2021-10-07T104852_edited.png
Dr. Luca Mazzarella, MD, Ph.D
Group Leader and Clinical Scientist at European Institute of Oncology (IEO), Milan, Italy
Limitations to widespread implementation of liquid biopsy